Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045472 · ClinicalTrials.gov registry record · Phase 1
A Study of VIS410 to Assess Safety and Pharmacokinetics
A Phase 1 study of Influenza, sponsored by Visterra.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02045472: Completed Phase 1 study of Influenza, sponsored by Visterra.
NCT02045472 is a Phase 1 study of Influenza that has completed, run by Visterra. The registered enrollment target is 41 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02045472, a Phase 1 study of Influenza, has completed, sponsored by Visterra.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.
Primary Outcome
Incidence of adverse events
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VIS410
Study Locations (1)
Minnesota
- DaVita Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT02045472 record still lists
NCT02045472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02045472 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02045472 about?
NCT02045472 is a clinical study titled "A Study of VIS410 to Assess Safety and Pharmacokinetics". The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.
What is the current status of trial NCT02045472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2014-09. Estimated completion is 2015-05.
What conditions does trial NCT02045472 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02045472?
The interventions under investigation include: Placebo (DRUG), VIS410 (DRUG).
Who is sponsoring clinical trial NCT02045472?
This trial is sponsored by Visterra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02045472 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02045472's enrollment target sits among peer trials
41 135th of 156 higher than 22 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia